For its fiscal second quarter ended March 31, 2026, Enanta Pharmaceuticals reported total revenue of $17.2 million, entirely derived from AbbVie's hepatitis C virus drug royalties, which marked an increase compared to the previous year. The company posted a net loss of $13.1 million (or $0.45 per diluted share), showing an improved bottom-line result year-over-year. Furthermore, it closed the quarter with $227.0 million in cash, cash equivalents, and marketable securities, providing a secure operating cash runway.